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ABSTRACT 
In Vitro Testing of Rifampicin and Fosmidomycin for Anti-Parasitic Activity against 
Theileria equi and Babesia caballi. (May 2013) 
 
W. Jacob Cobb 
Department of Biomedical Sciences 
Texas A&M University 
 
Research Advisor: Dr. Patricia J. Holman 
Department of Veterinary Pathobiology 
Texas A&M University 
 
Equine Piroplasmosis (EP) is a disease that negatively impacts the horse industry worldwide and 
is caused by two distinct species of protozoan parasites, Babesia caballi and Theileria equi. 
Currently the United States is considered free of EP and strict regulations are in place to prevent 
its introduction.  If an outbreak does occur, there are two options for infected horses: lifelong 
quarantine or humane euthanization.  Treatment options are limited in their ability to clear 
infection. Rifampicin and fosmidomycin are anti-microbial agents that are successful at treating 
related protozoan diseases, such as malaria. These two drugs were screened for anti-protozoal 
properties against the erythrocytic stage of T. equi and B. caballi by performing in vitro 
inhibition assays.  Parasite growth was evaluated over a 72 h treatment period and was 
significantly reduced for both species with notable morphological changes. Rifampicin was 
shown to possess more potent effects at lower concentrations than fosmidomycin for both T. equi 
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and B. caballi. Based on data acquired during the trial, further in vitro and in vivo tests should be 
performed for rifampicin and fosmidomycin. Further, the results attained suggest that other 
existing anti-microbials should be evaluated for their efficacy in treating EP.  
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NOMENCLATURE 
cELISA Competitive Enzyme-Linked Immunosorbent Assay 
CFT  Complement Fixation Test 
DOXP  2-C-methyl-D-erythritol 4-phosphate/1-deoxy-D-xylulose 5-phosphate 
DXP   1-deoxy-D-xylulose 5-phosphate 
EP  Equine Piroplasmosis 
IFA  Immunofluorescence Assay 
PCR  Polymerase Chain Reaction 
RBC  Red Blood Cells 
USDA  United States Department of Agriculture 
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CHAPTER I 
INTRODUCTION 
Equine Piroplasmosis (EP) is a disease in equids caused by one of two piroplasms: Babesia 
caballi or Theileria equi. These blood-borne parasites are transmitted by ticks to their host 
during feeding (Levine 1985). Piroplasms, of the order Piroplasmida, are members of a phylum 
of organisms that are obligate parasites called Apicomplexa (Allsopp et al., 1994; Wiser, 2012). 
The most striking feature of piroplasms is that they are obligate intraerythrocytic organisms of 
several genera, including Babesia and Theileria (Levine, 1985; Lack et al., 2012). Two other 
important features of these organisms are the presence of an organelle called an apicoplast which 
plays a role in the metabolic functioning of these single-celled organisms with notable 
similarities to that of the chloroplast in plants (Seeber and Soldati-Favre, 2010) and the presence 
of an apical complex which plays a role in host cell invasion and attachment (Tonkin, 2011). 
 
EP is enzootic in many regions in the world, including portions of Africa, Europe, Eurasia, the 
Caribbean and Central and South America (Schein, 1988; de Waal, 1992; Friedhoff and Soulé, 
1996; Rothschild and Knowles, 2007).  The pathology of the disease is dependent on the severity 
of infection with acute cases presenting with fever, anemia, icterus, swollen abdomen, and 
belabored breathing.  Death is not uncommon. In less severe disease, the clinical signs are 
weakness and a lack of appetite.  
 
EP is a disease of worldwide importance with negative implications on trade, importation, and 
exportation of equids.  EP is a reportable disease as defined by the World Organization for 
Animal Health (Katz et al., 1999). Specifically, international horse trade is impacted in that, for 
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many countries, negative test results for EP must be confirmed before a horse may enter an EP 
non-endemic country.  The United States has been declared free of EP since 1988 as a result of a 
joint eradication program put in place by the United States Department of Agriculture (USDA) 
and the Animal and Plant Health Inspection Services (APHIS), and a Florida State program 
specifically to eradicate B. caballi that began in 1962 (Brüning, 1996). However, due to the fact 
that the United States shares a land border with Mexico, an EP enzootic country, and the United 
States is a natural habitat of competent tick vectors for EP, the threat of reintroduction of the 
disease is constant (George et al., 2002). 
 
Prior to 1901, EP was called by many other names such as anthrax fever, bilious fever, and 
equine malaria (Roberts et al., 1962).  The name equine malaria was used because many of 
clinical signs of the disease are shared between malaria and EP.  In 1901, the intra-erythrocytic 
forms of the causative agents of EP were examined morphologically and named Piroplasma equi 
due to the fact that the protozoans assume a pear-shape that is characteristic of piroplasms 
(Laveran, 1901).  South African veterinarian Sir Arnold Theiler pioneered research on this 
disease trying unsuccessfully to infect unaffected horses via blood transfusions from afflicted 
animals.  He cited his inability to initiate disease in the unaffected horses as most likely due to 
one of two reasons:  either the horses were already immune to the infection or because a vector 
was needed for transmission, namely a tick (Theiler, 1902). Later, in 1912, it was discovered that 
EP was caused by two distinct organisms, Babesia equi (AKA Piroplasma equi) and Babesia 
caballi (Nuttall and Strickland, 1912). In 1998 Mehlhorn and Schein re-described B. equi as 
Theileria equi due to the fact that before T. equi invades the host erythrocyte, it first replicates 
inside a lymphocyte while Babesia sensu stricto parasites only replicate inside the erythrocytes.  
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Another differentiating factor is that T. equi can only be passed transstadially in the tick vector 
while Babesia parasites are passed both transstadially and transovarially (Mehlhorn and Schein, 
1998).  While there has been recent investigation as to whether T. equi should be considered a 
protozoan of the genus Theileria or rather of Babesia as previously (Traub-Dargatz et al., 2010), 
a definitive  conclusion has not been reached and for the remainder of this thesis the name 
Theileria equi (T. equi) will be used. 
 
One of the hallmark methods of diagnosing this disease has been and remains examination of 
stained thin blood smears.  The characteristic morphological aspects of T. equi and B. caballi 
make for a very confirmatory diagnosis upon seeing the infected erythrocytes of the equid in 
instances of high parasitemia (de Waal, 1992).  T. equi and B. caballi are morphologically 
distinct from each other in that B. caballi reproduces by forming two paired parasites inside one 
erythrocyte while T. equi forms a tetrad. The divided forms of B. caballi are larger than T. equi 
as well (Mehlhorn and Schein, 1998).   Definitive diagnosis is based on the divided forms with 
visualization of tetrads confirming infection with T. equi and paired piroplasms confirming 
infection with B. caballi. 
 
However, there are several other methods based on serology for reaching a diagnosis of EP.  The 
complement fixation test (CFT) was developed in 1945 by Hirato et al. It is also suggested that 
the CFT be used in combination with immunofluorescence assay (IFA).  Together these two tests 
can give a confirmatory diagnosis of EP (Weiland, 1986).  Also, a competitive enzyme-linked 
immunosorbent assay (cELISA) was developed by a group of researchers at Washington State 
University and the USDA’s Agricultural Research Service, and is now the official test that is 
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used in the United States for regulatory testing and detection of EP (Katz et al., 2003). 
Polymerase Chain Reaction (PCR) protocols have also been developed and are highly sensitive 
and specific to the detection of both these parasites (Possnet and Ambrosio, 1991; Possnet et al., 
1991).  
 
Previously the only confirmed natural vector of EP present in the United States was the tick 
Dermacentor (Anocenter) nitens which transmits B. caballi (Drummond et al., 1969). However, 
under experimental conditions it now has been shown that several other tick species are possible 
competent vectors of these agents in the United States.  Both Dermacentor variabilis and 
Dermacentor albipictus have been shown experimentally to be competent vectors of B. caballi 
while D. variabilis, Rhipicephalus (Boophilus) microplus, and Amblyomma cajennense have 
been shown experimentally to be competent vectors of T. equi (Stiller et al., 1980; Stiller et al., 
2002; Scoles et al., 2011).  This is important to note due to the fact that all of the ticks except 
R. microplus are found in the United States naturally.  
 
It should be noted that R. microplus, along with  Rhipicephalus annulatus, was eradicated from 
the United States in 1943 due to efforts to rid the country of the disease bovine babesiosis, which 
cost the United States large economic losses yearly (Graham and Hourrigan, 1977).  The United 
States is officially free of these ticks even though occasional outbreaks do occur.  This is due to 
the fact that the southern United States, principally Texas, shares a long land border with Mexico 
where the ticks in question are abundant.  Whenever an outbreak does occur, wide scale efforts 
are put in to place to control the spread via heavy quarantining and other methods. Since 1943 
Texas has had a permanent quarantine zone along the Rio Grande bordering Mexico, which is 
 
 
11 
 
meant to serve as a barrier to re-infestation with R. microplus and R. annulatus (Graham and 
Hourrigan, 1977).  However, a recent study has shown that the presence of R. microplus may be 
increasing in south Texas (Lohmeyer et al., 2011). 
 
The life cycles of the causative parasites of EP are similar.  In the host B. caballi sporozoites 
introduced at tick feeding invade erythrocytes where they then develop into trophozoites.  The 
trophozoites then grow and divide forming two merozoites.  The merozoites egress from the cell 
and are then capable of infecting more erythrocytes where more replication will occur. The 
merozoites also can differentiate into gametocytes which, when ingested by the tick vector, 
undergo a sexual stage and then multiply in various tick tissues, including the salivary glands and 
the ovaries (Levine, 1985).  The most notable difference for T. equi is that initially the 
sporozoites invade lymphatic cells forming schizonts.  The schizonts differentiate into 
merozoites which egress from the cell and then invade erythrocytes.  The merozoites then grow 
and transform into trophozoites which divide into a pear-shaped piroplasms in a tetrad formation. 
Again, the merozoites can differentiate into gametocytes which, when ingested by the vector, 
undergo development within the tick culminating in infective sporozoites in the salivary glands, 
but not in the ovaries and developing eggs (Zapf and Schein, 1994). 
 
Inside the vector tick, again T. equi and B. caballi differ in their transmission mechanisms.  
B. caballi is transmitted both transstadially and transovarially while T. equi is only passed 
transstadially (Ali et al., 1996). Transstadial transmission occurs when the parasite is passed 
between separate life stages of the tick vector.  Transovarial transmission occurs when the 
parasite is passed from the infected tick to the eggs of the next generation. 
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 D. variabilis and A. cajennense are three-host ticks meaning they feed on three separate hosts 
during their life cycle, while D. albipictus, D. nitens, and R. microplus are one host ticks 
meaning they feed on only one host during their 3-stage (larva, nymph, adult) life cycle (Oliver 
et al., 1987; Scoles et al., 2011). The distribution of the vector ticks is as follows: R. microplus is 
considered to be only present in the quarantine zone along the Texas/Mexico land border, 
D. nitens is found in south Texas and southern Florida, D. variabilis and D. albipictus are widely 
distributed across the United States, and A. cajennense is only present in southern United States 
(Estrada-Peña et al., 2004).    
 
Clearing of the agents of EP from an infected animal presents a challenging problem, especially 
for T. equi, due to the lack of effective drugs.  A recent study by Schwint et al. (2009) 
demonstrated that treatment with imidocarb dipropionate is effective at clearing an infection of 
B. caballi. However, an earlier study showed that repeated high-dosage treatment with the same 
drug was ineffective (Butler et al., 2008).  In general, it is accepted that imidocarb dipropionate 
is a valid treatment option for clearing infection with B. caballi (Correa et al., 2005). However 
the same cannot be said for T. equi.  Treatment with imidocarb dipropionate will not clear the 
infection (Correa et al., 2005; Kumar et al., 2003).  Infection with T. equi, as far as is known, is 
not able to be cleared under any current treatment protocols.  Several drugs (triclosan, artesunate, 
pyrimethamine, pamaquine, ponazuril, artemisinin derivatives, or buparvaquone) have shown 
promise with both theilerial-static and theilerial-cidal activities in vitro (Bork et al., 2003; Nagai 
et al., 2003; Wise et al., 2011). However, due to a lack of in vivo trials and pharmacokinetic 
studies on these drugs, further research must be done to investigate their efficacy against T. equi.  
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Because of the lack of effective clearing agents, specifically for infection with T. equi, this study 
evaluated the in vitro effectiveness of two candidate drugs. The two candidate drugs were tested 
alongside a positive control drug, diminazene aceturate.  Diminazene aceturate is considered a 
positive control due to its proven in vitro activity against T. equi and B. caballi, but it produces 
considerable adverse effects in the horse (Vial and Gorenflot, 2006). The two candidate drugs are 
fosmidomycin and rifampicin.   
 
Fosmidomycin is an antibiotic that is known to inhibit the non-mevalonate pathway or 2-C-
methyl-D-erythritol 4-phosphate/1-deoxy-D-xylulose 5-phosphate pathway (DOXP) pathway 
present in protozoans of the phylum Apicomplexa, of which T. equi and B. caballi are members 
(Kuzuyama et al., 1998; Kuzuyama et al., 2000).  It inhibits the action of 1-deoxy-D-xylulose 5-
phosphate reductoisomerase (DXP reductoisomerase), an enzyme of the DOXP pathway 
(Kuzuyama et al., 1998).  
 
Rifampicin is thought to act by inhibiting the DNA-dependent RNA polymerase present in 
prokaryotes (Strath et al., 1993). While T. equi and B. caballi are eukaryotes rather than 
prokaryotes, this drug has been shown to inhibit the growth of the closely related apicomplexan 
parasites Plasmodium spp. both in vitro and in vivo (Strath et al., 1993; Aditya et al., 2010). 
However, once the drug regimen was discontinued, recrudescence of malaria occurred (Strath et 
al., 1993).  Because T. equi, B. caballi and Plasmodium spp. are closely related piroplasms of the 
phylum Apicomplexa, it is not unlikely that rifampicin will exhibit anti-theilerial and anti-
babesial activity as well.   
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Taking all pertinent factors into consideration, it is hypothesized that treatment with 
fosmidomycin will exhibit theilericidal and babesiacidal activity against T. equi and B. caballi, 
respectively, while treatment with rifampicin will only exhibit static activity and once the 
treatment regimen is ceased, recrudescence will occur for both T. equi and B. caballi. 
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CHAPTER II 
MATERIALS AND METHODS 
 
Equine donor erythrocyte preparation and storage 
Donor blood from a 22 year old female Tennessee Walking Horse (Equus ferrus caballus) was 
collected via jugular venipuncture into a 30 mL syringe containing 15 mL of Alsever’s solution 
in compliance with the approved animal use protocol (TAMU AUP 2012-218, PI Dr. Patricia J. 
Holman). Following blood collection, the blood was transferred to a 50 mL centrifuge tube and 
centrifuged for 15 min at 330 X g at approximately 10°C and stored at 4°C until further 
preparation was needed.  When donor erythrocytes were required, 1 volume of packed red blood 
cells (RBC) was added to 7 volumes of Dulbecco’s Phosphate Buffered Saline (DPBS) 
(HyClone Laboratories, Logan, UT) and resuspended thoroughly in a 2 mL microcentrifuge tube.  
The resuspended erythrocytes were centrifuged in a microcentrifuge at 820 X g for 3 min at 
room temperature (RT).  The supernatant was discarded.  This wash procedure was repeated 
twice more for a total of 3 washes.  After the supernatant was removed from the last wash, 5 
volumes of Puck’s Saline Glucose with 20 g/L extra glucose (PSG+G) (Holman et al., 1988) 
were added to each microcentrifuge tube which was then centrifuged once more as above and 
stored at 4°C until use.   
 
Resuscitation of Babesia caballi and Theileria equi cultures from cryopreserved stocks 
Media formulations were as follows.  Theileria equi HL-20 Complete Media (HL-20 CTE) was 
composed of 20% fetal bovine serum (V/V; Hyclone Laboratories), 2 mM L-glutamine, 
1 mg/mL AlbuMAX I (GIBCO, Grand Island, NY), 16 µM thymidine (HT Supplement; 
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GIBCO), 100 U/mL penicillin, 100 µg/mL streptomycin per mL, 25 µg/mL amphotericin B 
(Fungizone) (antibiotic-antimycotic solution, GIBCO), 2% HB 101 supplement (V/V after 
following manufacturer's instructions on reconstitution of the lyophilized supplement; Irvine 
Scientific, Santa Ana, CA) in HL-1 medium (Lonza, Walkersville, MD, USA) (Holman et al., 
1994). Babesia caballi HL-20 Complete Media (HL-20 CBC) was composed of 20% normal 
adult horse serum (V/V; Atlanta Biologicals, Lawrenceville, GA), 2 mM L-glutamine,  and 
antibiotic-antimycotic as above, in HL-1 medium (Holman et al., 1993).  Media were sterile 
filtered (0.45 micron filter) and stored at 4°C.  
 
Babesia caballi (USDA strain) and T. equi (USDA strain) cryostocks were resuscitated from 
liquid nitrogen storage according to standard protocols (Holman et al., 1993 & 1994).  The 
parasites were cultured in 24-well plates.  The total well volume for initiation and maintenance 
of cultures, 1.25 mL, contained 900 µL media, 100 µL washed donor horse RBC, and 250 µL 
cryopreserved culture of T. equi at passage 18 and B. caballi at passage 32, which had been 
rapidly thawed by swirling the vial in a waterbath at 37°C. Each day, 900 µL of medium 
overlying the settled RBC layer was removed and replaced with fresh medium.  At that time,  
thin erythrocyte smears were made from 0.5 µL of the B. caballi and T. equi settled erythrocytes 
in culture, methanol fixed, and stained for 45 min in a 1:15 Giemsa:H2O solution (Accustain, 
Sigma, St. Louis, MO).  Following staining, the smears were rinsed with distilled water for 1 min 
to remove excess stain and debris and allowed to air dry.  Examination of the thin erythrocyte 
films was done at 1000X magnification under oil immersion light microscopy.  Before reaching 
parasitemias suitable for routine subculturing, the entire smear was examined.  One hundred 
microliters of fresh RBC was added to each well on a weekly basis.   
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Once 7 parasites per 1000X field were seen in at least 2 fields under oil immersion, a subculture 
was performed by adding to each new well 250 µL culture, 900 µL complete media, and 100 µL 
washed RBC to achieve a subculture ratio of 1:5 for both B. caballi and T. equi (passage 33 and 
19, respectively).   When the cultures consistently maintained at least 7 parasites per 1000X field 
in at least 2 fields under oil immersion light microscopy, a regular subculturing regimen was 
adopted.  B. caballi cultures were subcultured every 72 h and T. equi cultures were subcultured 
every 48 h, with daily replenishing of the medium.   
 
Drug trials 
Diminazene aceturate (Sigma-Aldrich, St. Louis, MO), fosmidomycin (Invitrogen, Grand Island, 
NY), and rifampicin (Sigma, St. Louis, MO) were solubilized to stock concentrations of 50 mM, 
50 mM, and 30 mM in ultrapure water containing 10%, 10%, and 50% dimethyl sulfoxide 
(DMSO) (V/V), respectively. The stock solutions were stored at -20°C until use.  At use, the 
stocks were thawed at RT and an appropriate volume was added to HL-1 medium to yield 
0.5 mM working solutions for diminazene aceturate and fosmidomycin, and a 0.3 mM working 
solution for rifampicin. Concentrations of diminazene aceturate used as positive controls were 
2.4 µM and 6.0 µM for B. caballi and T. equi, respectively. The concentrations of rifampicin and 
fosmidomycin used in the drug trials are shown in Table 1 and Table 2.  
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Table 1 
Concentrations of rifampicin and fosmidomycin tested for inhibition of Theileria equi in vitro  
  Rifampicin (µM)    Fosmidomycin (µM)   
 3.75 
7.5 
15 
   8 
16 
32 
  
 
 
 
 
 
 
Table 2 
Concentrations of rifampicin and fosmidomycin tested for inhibition of Babesia caballi in vitro  
  Rifampicin (µM)    Fosmidomycin (µM)   
 3.75 
7.5 
15 
   8 
16 
 32  
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The drug-containing media for the trials were made by adding the appropriate amount of 0.3 mM 
or 0.5 mM working solution to HL-20 CTE for T. equi or HL-20 CBC for B. caballi.  DMSO 
control media were prepared by adding an aliquot of 50% solution of DMSO in ultrapure water 
to HL-20 CTE or HL-20 CBC to mimic the maximum concentration of DMSO in the drug-
containing media.  Negative control media were HL-20 CBC for B. caballi and HL- 20 CTE for 
T. equi. 
 
The cultures were adjusted to obtain a standard starting inoculum parasitemia of 2% as follows.  
First, hematocrits of regularly maintained T. equi and B. caballi cultures were determined by 
resuspending the cultured cells and drawing 30 µL into a mini-hematocrit capillary tube and then 
sealing the end. Centrifugation in a hematocrit centrifuge followed and the hematocrit was then 
read according to the manufacturer’s instructions (Damon, IEC Division, Needham, MA). 
Aliquots of 200 µL of culture were centrifuged in a table-top centrifuge at 820 X g for 3 min at 
RT and thin erythrocyte smears were made from the cell pellets in triplicate and stained as 
above.  To determine the parasitemia of the cultured cells, the number of parasitized and non-
parasitized erythrocytes were tallied separately (Fisher Differential Counter Model 111, Fisher 
Scientific, Pittsburgh, PA) in each of 10 fields of approximately 100 cells each (total of 1000 
cells) at 1000X magnification under oil immersion light microscopy.  The total number of 
parasitized RBC was then divided by 1000 and multiplied by 100 to give a percent parasitemia. 
An average percent parasitemia was calculated from the values of the triplicate smears.  Washed 
donor RBC were prepared as above and the hematocrit adjusted with complete HL-1 medium to 
that of the culture and then added to the culture at a factor so as to achieve a 2% parasitemia.  To 
confirm the starting parasitemia of 2% for the trial, the hematocrit of the adjusted culture was 
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then measured as above and triplicate Giemsa-stained thin erythrocyte smears were made and 
percent parasitemias were calculated as above.   
 
To 12 wells in a 96 well plate 75 µL of the inoculum was plated along with 75 µL of a 2X 
drug or DMSO-containing media  (which resulted in a 1X drug or DMSO concentration), or 
negative control medium for each drug concentration to be tested. To provide adequate humidity 
to prevent the wells from drying out, 200 µL of sterile ultrapure water was added to all the 
outermost wells of the plate.  Every 24 h for 3 d 100 µL of medium overlying the settled 
erythrocytes was removed from each well and replaced with 100 µL fresh 1X drug-containing, 
negative control, or DMSO medium as appropriate.  For each parasite, trials with rifampicin and 
fosmidomycin were performed in tandem using the same negative, positive, and DMSO control 
cultures for both drugs. Thin erythrocyte smears were made from 3 separate wells every 24 h and 
stained and examined as above.  The percent parasitemias and average percent parasitemias of 
the matched triplicate samples were recorded.  After 72 h of drug treatment, the medium was 
replaced with drug-free complete medium.  At 96 h, the cultures were evaluated for parasites that 
appeared viable.   If intact, normal-appearing parasites were detected, the cultures were 
terminated.  If not, the cultures were monitored until recrudescence occurred or maintained for 
an additional 14 d by replenishing with drug-free medium as above. 
 
Based on the trial data, further trials with T. equi were performed over appropriate ranges of drug 
concentrations as shown in Table 3 and Table 4 in the same manner as described.  
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Table 3 
 Concentrations of rifampicin and fosmidomycin tested for inhibition of Theileria equi in vitro  
   
Rifampicin (µM)  Fosmidomycin (µM) 
0.75  1.5 
1.5  3 
3 
6 
12 
 6 
12 
24 
 
 
 
 
 
 
Table 4 
 Concentrations of rifampicin and fosmidomycin tested for inhibition of Theileria equi in vitro  
   
Rifampicin (µM)  Fosmidomycin (µM) 
15 
30 
60 
32 
64 
100 
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Determination of IC50 
The average percent parasitemias at 72 h for each drug concentration and the negative control 
were input into a Microsoft Excel graph and a trendline was added (either linear or power-based 
as appropriate to its best fit).  Using the equation obtained by this process, the  IC50 was -
calculated and reported. 
 
Data collection and analysis 
During trials triplicate percent parasitemias were determined and recorded in Microsoft Excel.  
For each set of triplicate wells, average percent parasitemia was calculated and tested in 
Student’s t-tests to compare the parasitemias between the trial drug, positive control, and 
negative control cultures.  P values of ≤ 0.05 were considered statistically significant. 
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CHAPTER III 
RESULTS 
 
Theileria equi 
Initially, rifampicin was tested at 3.75, 7.5, and 15.0 µM against T. equi (Table 1, Fig. 1A).  The 
negative control and DMSO-treated cultures showed maximum parasitemias of 23.8% and 
22.8% respectively at 72 h as shown in Table 5.  These cultures showed no difference in growth 
statistically (P > 0.20).  The positive control cultures, which were treated with 6.0 µM 
diminazene aceturate, reached a maximum parasitemia of 2.6% at 72 h (Table 5, Fig. 1A).  This 
was significantly inhibited when compared with the negative control cultures (P
 
< 0.001). The 
cultures treated with 3.75, 7.5, and 15.0 µM rifampicin reached maximum parasitemias of 
13.0%, 11.3%, and 10.5% respectively at 72 h (Table 5).  Each of these was statistically 
significantly inhibited in comparison with the negative control cultures (P < 0.001, P < 0.001, 
P < 0.001, respectively).   
 
Fosmidomycin was tested at 8.00, 16.0, and 32.0 µM against T. equi alongside the rifampicin 
trial (Fig. 1B). As such, the control data is the same. The cultures treated with 8.0, 16.0, and 
32.0 µM fosmidomycin reached maximum parasitemias of 16.0%, 13.5%, and 12.2% 
respectively at 72 h (Table 5, Fig. 1B).  Each of these was inhibited significantly in comparison 
with the negative control cultures (P < 0.003,
 
P < 0.001, P < 0.001, respectively).  
 
Following this initial trial, a second trial was performed (Fig. 2).   Rifampicin was tested at 
concentrations of 0.75, 1.5, 3.0, 6.0, and 12.0 µM against T. equi (Fig. 2A).  The negative control 
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and DMSO- treated cultures reached maximum parasitemias of 21.6% and 20.4% respectively at 
72 h as shown in Table 6.  There was no statistical difference between the growth rates of these 
two cultures (P > 0.30). T. equi control cultures treated with 6.0 µM diminazene aceturate 
attained a maximum parasitemia of 2.9% (Table 6) at 72 h and were significantly inhibited when 
compared with the negative control cultures (P < 0.001).  The cultures treated with 0.75, 1.5, 3.0, 
6.0, and 12.0 µM rifampicin reached maximum parasitemias of 16.5%, 15.6%, 13.6%, 12.9%, 
and 9.6% respectively at 72 h (Table 6).  Each of these was significantly inhibited in comparison 
with the negative control cultures (P < 0.002, P < 0.001, P < 0.001, P < 0.001, P < 0.001, 
respectively).  Fosmidomycin was tested at 1.5, 3.0, 6.0, 12.0, and 24.0 µM against T. equi (Fig. 
2B) alongside the rifampicin trial, so the control culture data is the same for both drugs.   
Maximum parasitemias of 16.9%, 15.4%, 15.3%, 13.6%, and 12.1% were attained at 72 h for 
treatment with 1.5, 3.0, 6.0, 12.0, and 24.0 µM fosmidomycin, respectively (Table 6).  Each of 
these cultures was significantly inhibited with comparison to the negative control cultures 
(P < 0.001, P < 0.001, P < 0.001, P < 0.001, P < 0.001, respectively).  
  
In the last trial performed with T. equi, rifampicin was tested at 15.0, 30.0, and 60.0 µM 
(Fig. 3A). Negative control and DMSO-treated cultures reached maximum parasitemias of 
19.7% and 19.5% at 72 h (Table 7) with no statistical difference in their growth (P > 0.50).  
Cultures treated with 6.00 µM diminazene aceturate attained a maximum parasitemia of 2.6% at 
72 h (Table 7) and were significantly different from the negative control cultures (P < 0.001). 
Maximum parasitemias 10.7%, 9.5%, and 7.5%, respectively, were attained at 72 h (Table 7).  
Each of these cultures was significantly inhibited compared to the negative control cultures 
(P < 0.001, P < 0.001, P < 0.001, respectively). Fosmidomycin was tested 32.0, 64.0, and 
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100.0 µM against T. equi (Fig. 3B) alongside the rifampicin trial, so the control culture data is 
the same for both drugs.  Maximum parasitemias of 12.5%, 10.3%, and 8.1% were attained at 
72 h for treatment with 32.0, 64.0, and 100.0 µM fosmidomycin, respectively (Table 7). Each of 
these cultures was significantly inhibited with comparison to the negative control cultures 
(P < 0.002, P < 0.001, P < 0.001, respectively). Distinct morphological changes were observed 
in the cultured parasites treated with rifampicin, fosmidomycin and diminazene aceturate in 
comparison with those that were not treated or treated with DMSO only as shown in Figure 4.  In 
the cultures treated with rifampicin, fosmidomycin, or diminazene aceturate a dot forms of the 
parasite predominated (Fig. 4).  
 
The IC50 determined for T. equi treated with rifampicin is 22.86 µM. The equation obtained from 
the graph in Microsoft Excel is shown below. 
Equation 1:  y = 0.0057x
2
 - 0.5349x + 19.115 
 The R
2
 coefficient obtained via this analysis is equal to 0.9471, suggesting a high degree of 
correlation.  
 
The IC50 for T. equi treated with fosmidomycin is 58.51 µM. The equation obtained from the 
graph in Microsoft Excel is shown below.  
Equation 2:  y = 0.0012x
2
 - 0.2347x + 19.491 
 The R
2
 coefficient obtained via this analysis is equal to 0.9856, suggesting a high degree of 
correlation. 
 
 Upon removal of drug pressure, parasite growth resumed in all instances for T. equi (Table 8). 
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Fig. 1. (A) In vitro growth inhibition trials of T. equi against a range of concentrations of 
rifampicin; (B) In vitro growth inhibition trials of T. equi against a range of concentrations of 
fosmidomycin. Bars show standard deviations.  Points with an asterisk (*) exhibit statistically 
significant inhibition of growth.  
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Table 5 
Average percent parasitemias of T. equi at 72 h treated with rifampicin and fosmidomycin.  
Cultures treated with complete media, DMSO, and 6.0 µM diminazene aceturate served as 
controls. P values were calculated using a Student’s t-test between the ‘No Treatment’ control 
and the drug treatment percent parasitemias.  P values < 0.05 are considered statistically 
significant.  
Treatment Average Percent Parasitemia P Value 
No Treatment 
DMSO 
23.8±1.46 
22.8±0.361 
N/A 
> 0.200 
 
6.0 µM Diminazene Aceturate 2.6±0.322 < 0.001
  
3.75 µM Rifampicin 13.0±0.416        < 0.001
 
7.5 µM Rifampicin 11.3±0.721        < 0.001
 
15.0 µM Rifampicin 10.5±0.351        < 0.001
 
8.0 µM Fosmidomycin 16.0±1.56 < 0.003
 
16.0 µM Fosmidomycin 13.5±0.503 < 0.001
 
32.0 µM Fosmidomycin 12.2±0.808 < 0.001
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Fig. 2. (A) In vitro growth inhibition trials of T. equi against a range of concentrations of 
rifampicin; (B) In vitro growth inhibition trials of T. equi against a range of concentrations of 
fosmidomycin. Bars show standard deviations.  Points with an asterisk (*) exhibit statistically 
significant inhibition of growth. 
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Table 6 
Average percent parasitemias of T. equi at 72 h treated with rifampicin and fosmidomycin.  
Cultures treated with complete media, DMSO, and 6.00 µM diminazene aceturate served as 
controls. P values were calculated using a Student’s t-test between the ‘No Treatment’ control 
and the drug treatment percent parasitemias.  P values < 0.05 are considered statistically 
significant. 
Treatment Average Percent Parasitemia P Value 
No Treatment 
DMSO 
21.6±0.361 
20.4±1.80 
N/A 
 < 0.300 
6.0 µM Diminazene Aceturate 2.9±0.200 < 0.001 
0.75 µM Rifampicin 16.5±1.25 < 0.002
 
1.5 µM Rifampicin 15.6±0.400 < 0.001 
3.0 µM Rifampicin 13.6±0.557 < 0.001 
6.0 µM Rifampicin 12.9±0.794 < 0.001 
12.0 µM Rifampicin 9.6±0.551 < 0.001 
1.5 µM Fosmidomycin     16.9±0.436       < 0.001
 
3.0 µM Fosmidomycin     15.4±0.907       < 0.001
 
6.0 µM Fosmidomycin  15.3±0.351       < 0.001
 
12.0 µM Fosmidomycin  13.6±0.451       < 0.001
 
24.0 µM Fosmidomycin  12.1±0.100       < 0.001
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Fig. 3 (A) In vitro growth inhibition trials of T. equi against a range of concentrations of 
rifampicin; (B) In vitro growth inhibition trials of T. equi against a range of concentrations of 
fosmidomycin. Bars show standard deviations.  Points with an asterisk (*) exhibit statistically 
significant inhibition of growth. 
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Table 7  
Average percent parasitemias of T. equi at 72 h treated with rifampicin and fosmidomycin.  
Cultures treated with complete media, DMSO, and 6.00 µM diminazene aceturate served as 
controls. P values were calculated using a Student’s t-test between the ‘No Treatment’ control 
and the drug treatment percent parasitemias.  P values < 0.05 are considered statistically 
significant. 
 
Treatment 
Average Percent 
Parasitemia 
 
P Value 
No Treatment 19.7±0.404 N/A 
DMSO 19.5±0.252 > 0.500 
6.0 µM Diminazene Aceturate 2.6±0.361 < 0.001
 
32.0 µM Fosmidomycin 12.5±0.173 < 0.001
 
64.0 µM Fosmidomycin 10.3±0.153 < 0.001
 
100 µM Fosmidomycin 8.1±0.361 < 0.001
 
15.0 µM Rifampicin 10.7±0.379 < 0.001
 
30.0 µM Rifampicin 9.5±0.611 < 0.001
 
60.0 µM Rifampicin 7.5±0.153 < 0.001
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Fig. 4.  Giemsa-stained thin erythrocyte smears from 72 h Theileria equi cultures under different 
treatment protocols (1000X). (A) Normal culture, no treatment showing various normal 
morphological forms;  (B) 6.0 µM diminazene aceturate showing the positive control drug effect; 
(C) 32.0 µM fosmidomycin; and (D) 15.0 µM rifampicin. The larger arrow indicates normal T. 
equi morphology.  Short, thin arrows indicate T. equi condensed dot forms. 
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Table 8 
Presence of normal-appearing Theileria equi parasites at 96 h after no drug treatment for 24 h 
under different treatment protocols.  
Treatment Presence of Normal-Appearing         
Parasites at 96 h 
Negative Control + 
DMSO + 
6.0 µM Diminazene Aceturate + 
0.75 µM Rifampicin + 
1.5 µM Rifampicin + 
3.0 µM Rifampicin + 
3.75 µM Rifampicin + 
6.0 µM Rifampicin + 
7.5 µM Rifampicin + 
12.0 µM Rifampicin + 
15.0 µM Rifampicin + 
30.0 µM Rifampicin + 
60.0 µM Rifampicin + 
1.5 µM Fosmidomycin + 
3.0 µM Fosmidomycin + 
6.0 µM Fosmidomycin + 
8.0 µM Fosmidomycin + 
12.0 µM Fosmidomycin + 
16.0 µM Fosmidomycin + 
24.0 µM Fosmidomycin + 
32.0 µM Fosmidomycin + 
64.0 µM Fosmidomycin + 
100.0 µM Fosmidomycin + 
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Babesia caballi 
Initially, rifampicin was tested at 3.75, 7.5, and 15.0 µM against B. caballi (Fig. 5A).  The 
negative control and DMSO-treated cultures reached maximum parasitemias of 9.0% and 8.9% 
respectively at 72 h (Table 9).  These parasitemias showed no difference statistically (P > 0.750).  
The positive control cultures, which were treated with 2.4 µM diminazene aceturate, reached a 
parasitemia of 0.0% at 72 h (Table 9).  This was significantly inhibited when compared with the 
negative control cultures (P < 0.001). The cultures treated with 3.75, 7.5, and 15.0 µM 
rifampicin reached maximum parasitemias of 5.3%, 4.5%, and 4.0% respectively at 72 h 
(Table 9).  Each of these was statistically significantly inhibited in comparison with the negative 
control cultures (P < 0.001, P < 0.001, P < 0.001, respectively).  Fosmidomycin was tested at 
8.0, 16.0, and 32.0 µM against B. caballi (Fig. 5B) alongside the rifampicin tests in Figure 5A.  
As such, the control data is the same. The cultures treated with 8.0, 16.0, and 32.0 µM 
fosmidomycin reached maximum parasitemias of 3.7%, 2.8%, and 2.3% respectively at 72 h 
(Table 9).  Each of these was also inhibited significantly in comparison with the negative control 
cultures (P < 0.001, P < 0.001, P < 0.001, respectively).  
 
Distinct morphological changes were noticed in the cultures treated with rifampicin, 
fosmidomycin and diminazene aceturate in comparison with those that were treated with either 
DMSO or negative control media.  The morphology of the parasites under their separate 
treatment protocols is demonstrated in Figure 7.  In the cultures treated with rifampicin, 
fosmidomycin, or diminazene aceturate condensed dot forms of B. caballi predominated (Fig. 6). 
The IC50 for B. caballi treated with rifampicin is 6.42. µM. The equation obtained from the graph 
in Microsoft Excel is shown below. 
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Equation 3:  Y = 0.0411x
2
 – 0.9284x + 8.7494 
 The R
2
 coefficient obtained via this analysis is equal to 0.9618, suggesting a high degree of 
correlation.  
 
The IC50 for B. caballi treated with fosmidomycin is 8.24 µM. The equation obtained from the 
graph in Microsoft Excel is shown below.  
Equation 4: Y = 0.0131x
2
 – 0.14x + 8.6512 
 The R
2
 coefficient obtained via this analysis is equal to 0.9572 suggesting a high degree of 
correlation. 
 
Upon removal of drug pressure, parasite growth resumed in all instances for B. caballi except for 
those cultures treated with 2.40 µM diminazene aceturate (Table 10). 
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 Fig. 5.  (A) In vitro growth inhibition trials of Babesia caballi against a range of concentrations 
of rifampicin. (B) In vitro growth inhibition trials of B. caballi against a range of concentrations 
of fosmidomycin. Bars show standard deviations.  Points with an asterisk (*) exhibit statistically 
significant inhibition of growth. 
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Table 9 
Average percent parasitemias of Babesia caballi at 72 h treated with rifampicin and 
fosmidomycin. Cultures treated with complete media (No Treatment), DMSO, and 2.4 µM 
diminazene aceturate served as controls. P values were calculated using a Student’s t-test 
between the ‘No Treatment’ control and the drug treatment percent parasitemias. P values < 0.05 
are considered statistically significant. 
Treatment Average Percent Parasitemia P Value 
No Treatment 
DMSO 
8.97±0.252 
8.87±0.451 
N/A 
> 0.750 
2.40 µM Diminazene Aceturate 0.03±0.058 < 0.001
 
3.75 µM Rifampicin 5.27±0.208 < 0.001
 
7.50 µM Rifampicin 4.53±0.306 < 0.001
 
15.0 µM Rifampicin 4.00±0.361 < 0.001
 
8.00 µM Fosmidomycin  3.73±0.208 < 0.001 
16.0 µM Fosmidomycin 2.80±0.100 < 0.001 
32.0 µM Fosmidomycin 2.27±0.208 < 0.001 
. 
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Fig. 6.  Giemsa-stained thin erythrocyte smears from 72 h Babesia caballi cultures under 
different treatment protocols (1000X). (A) Normal culture, no treatment showing various normal 
morphological forms; (B)  2.4 µM diminazene aceturate showing the positive control drug effect; 
(C) 32.0 µM fosmidomycin; and (D) 15.0 µM rifampicin. The larger arrow indicates normal B. 
caballi morphology.  The short, thin arrows indicate B. caballi condensed dot forms. 
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Table 10 
Presence of normal-appearing Babesia caballi parasites at 96 h after no drug treatment for 24 h 
under different treatment protocols.  
Treatment Presence of Normal-Appearing         
Parasites at 96 h 
Negative Control + 
DMSO + 
2.40 µM Diminazene Aceturate - 
3.75 µM Rifampicin + 
7.5 µM Rifampicin + 
15 µM Rifampicin + 
8.00 µM Fosmidomycin + 
16.0 µM Fosmidomycin + 
32.0 µM Fosmidomycin + 
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CHAPTER IV 
CONCLUSIONS 
The aim of this study was to determine the anti-protozoal activity of fosmidomycin and rifampicin 
against the etiological agents of EP.  Specifically, it was hypothesized that fosmidomycin would exhibit 
theilericidal and babesiacidal activity against Theileria equi and Babesia caballi, respectively while 
rifampicin would only exhibit static activity of parasite growth.  This study successfully demonstrated 
anti-protozoal activity against the agents of EP, although the hypothesis tested was not proven.  The 
significant inhibition of parasite growth and identification of the IC50 for both of these drugs for both 
parasites clearly indicates that there is in vitro inhibition of parasite growth.   
 
Based on this study it cannot be said if fosmidomycin exhibits theilericidal and babesiacidal activity 
against T. equi and B. caballi, respectively.  Morphological examination of the thin erythrocyte smears 
from drug-exposed cultures showed what appeared to be a higher proportion of condensed dot forms for 
both T. equi and B. caballi with both fosmidomycin and rifampicin.  However, our study did not ascertain 
whether these were viable parasites or not.   
 
Complete clearance of the parasite from the blood continues to be the goal for treatment of EP.  This is 
because even after the signs of disease regress, equids can remain carrier animals, serving as potential 
reservoirs for future infective outbreaks of EP.  For this reason, the trade of EP positive horses is highly 
restricted.  Therefore, there is a clear and pressing need for the identification of treatment that will not 
only alleviate disease, but clear infection as well.  This study was not successful in demonstrating the 
ability to clear infection with either drug for either parasite under in vitro conditions.  However, further 
trials for longer treatment periods and/or with higher drug concentrations are warranted.  There is a need 
to determine if a longer treatment period is associated with complete elimination of EP infection.   
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Due to the pronounced anti-protozoal activity demonstrated by rifampicin and fosmidomycin alone, 
studies testing combinations of the drugs should be performed in order to elucidate if synergism exists 
with these drugs.  Also, in vivo trials should be done to determine if rifampicin and fosmidomycin could 
serve as possible drugs for EP treatment.  Rifampicin is approved for use in equids whereas 
fosmidomycin has not been approved (Kohn et al., 1993).   
 
In this study, anti-microbials that had not been tested against EP were found to be effective at depressing 
parasitemia levels in vitro.  The positive results of this study indicate a need for examination of other  
anti-microbials for their efficacy at treating EP.  Due to the constant threat of introduction of EP, this 
research should be considered a priority for equine veterinary researchers in the United States.  
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